-
公开(公告)号：KR1020140134994A
公开(公告)日：2014-11-25
申请号：KR1020130055158
申请日：2013-05-15
IPC: A61K35/12 , A61K38/30 , A61K31/375 , A61K9/08
CPC classification number: A61K9/0019 , A61K35/28 , A61K47/46 , C12N5/0667 , C12N2500/38 , C12N2500/44 , C12N2501/06 , C12N2501/11 , C12N2501/115 , C12N2501/33 , C12N2501/39 , C12N2501/91 , C12N2501/999 , C12N2509/00
Abstract: 본 발명은 10 내지 20 ㎛의 직경을 가지고, 단세포로 존재하는 줄기세포를 1 X 10
7 ~ 5 X 10
8 세포수/ml로 함유하는 것을 특징으로 하는 정맥 투여용 줄기세포 조성물에 관한 것이다.
본 발명에 따르면, 정맥 투여에 적합한 줄기세포 조성물을 제공할 수 있어, 혈관 내로 투여된 줄기세포가 안정적으로 표적 조직에 도달하여 활성을 나타내는 효능을 보다 효율적으로 높일 수 있으므로 줄기세포를 이용한 세포치료 효능을 획기적으로 증진시킬 수 있다.Abstract translation: 本发明涉及静脉内给药的干细胞组合物，其含有1×10 7〜5×10 8细胞/ ml干细胞，其直径为10〜20μm，作为单细胞存在。 本发明通过提供适用于静脉内给药的干细胞组合物，从而通过使用干细胞来促进治疗细胞的功效，因为在血管中施用的干细胞稳定地达到目标组织，并通过提供适合于静脉内施用的干细胞组合
-
公开(公告)号：KR101425653B1
公开(公告)日：2014-08-05
申请号：KR1020070042645
申请日：2007-05-02
Inventor： 라정찬
Abstract: 본 발명은 인간 지방조직 유래 성체 줄기세포 및 두피조직 유래 모낭세포를 함유하는 발모유도용 세포치료제에 관한 것으로, 더욱 자세하게는 인간 지방조직 유래 성체 줄기세포, 및 CD34 양성 및/또는 음성세포를 함유하는 두피조직 유래 모낭세포가 일정 혼합비율로 함유되어 있는 발모유도용 세포치료제에 관한 것이다.
본 발명에 따른 발모유도용 세포치료제는 탈모증 및 무모증을 포함하는 모낭형성이 정상적으로 이루어지지 않아 발생하는 증상에 적용하여 발모의 효능을 이끌어 내는데 유용하다.
지방조직 유래, 성체 줄기세포, 모낭세포, 탈모치료, 발모-
公开(公告)号：KR1020140083881A
公开(公告)日：2014-07-04
申请号：KR1020130159373
申请日：2013-12-19
IPC: G01N33/497 , G01N33/574
CPC classification number: A61B5/082 , G01N30/7206 , G01N33/0047 , G01N33/57488 , G01N2030/8804 , G01N2030/884 , G01N2033/4975
Abstract: The present invention relates to a method for diagnosing cancer which is characterized by detecting a volatile organic compound specifically comprised in an exhaled gas of a cancer patient and, more specifically, to a method for providing information for diagnosing cancer comprising a step of measuring the presence of a substance having the molecular weight (i) 69, (ii) 131, and (iii) 181 which is an ionized fragment of a cancer-specific VOC from an exhaled gas taken from a suspected cancer patient. According to the present invention, a cancer can be early diagnosed non-invasively from an exhaled gas of a cancer patient with high sensitivity, therefore the cancer can be economically and rapidly diagnosed compared with an existing cancer diagnosis method.
Abstract translation: 本发明涉及一种诊断癌症的方法，其特征在于检测特异性地包含在癌症患者的呼出气体中的挥发性有机化合物，更具体地，涉及提供用于诊断癌症的信息的方法，包括测量存在的步骤 具有分子量（i）69，（ii）131和（iii）181的物质，其是来自疑似癌症患者的呼出气体的癌症特异性VOC的离子化片段。 根据本发明，可以从具有高灵敏度的癌症患者的呼出气体非侵入性地早期诊断癌症，因此与现有的癌症诊断方法相比，可以经济地和快速地诊断癌症。
-
Patent Agency Ranking
公开(公告)号：KR1020130117343A
公开(公告)日：2013-10-25
申请号：KR1020130042517
申请日：2013-04-17
IPC: C12N5/074 , C12N5/02 , C12N5/0775
CPC classification number: C12N5/0667 , C12N2500/14 , C12N2500/32 , C12N2500/38 , C12N2501/11 , C12N2501/115 , C12N2501/33 , C12N2501/39
Abstract: PURPOSE: A method for producing stem cells with a size suitable for intravascular administration is provided to help stem cells to easily move to a target tissue and to obtain the stem cells with superior stability, thereby remarkably enhancing cell therapeutic efficiency by intravascular administration of the stem cells. CONSTITUTION: A method for producing stem cells with a size suitable for intravascular administration comprises the step of culturing stem cells in a basic medium and a medium containing two or more ingredients selected among N-acetyl-L-cysteine, insulin or insulin-like factors, hydrocortisone, basic fibroblast growth factor (bFGF), and an antioxidant. The basic medium is selected among M199/F12 mixture (GIBCO), alpha-minimal essential medium (Welgene), low concentration glucose-containing DMEM (Welgene), MCDB 131 (Welgene), IMEM (GIBCO), K-SFM, DMEM/F12, PCM, and MSC (Chemicon). [Reference numerals] (AA) KSFM+ addictive
Abstract translation: 目的：提供一种适用于血管内给药的干细胞的制备方法，以帮助干细胞容易地移动到目标组织，获得具有优异稳定性的干细胞，从而通过血管内施用茎显着提高细胞治疗效率 细胞。 构成：适用于血管内给药的干细胞的制造方法包括在碱性培养基和含有选自N-乙酰-L-半胱氨酸，胰岛素或胰岛素样因子中的两种以上成分的培养基中培养干细胞的步骤 ，氢化可的松，碱性成纤维细胞生长因子（bFGF）和抗氧化剂。 基本培养基选自M199 / F12混合物（GIBCO），α-最小必需培养基（Welgene），低浓度葡萄糖DMEM（Welgene），MCDB 131（Welgene），IMEM（GIBCO），K-SFM，DMEM / F12，PCM和MSC（Chemicon）。 （标号）（AA）KSFM +上瘾
-
公开(公告)号：KR1020130116213A
公开(公告)日：2013-10-23
申请号：KR1020130041022
申请日：2013-04-15
IPC: C12N5/074 , C12N5/0775 , A61K35/12
CPC classification number: A61K35/28 , A61K31/616 , C12N5/0667 , C12N2500/30 , C12N2501/71 , C12N2501/999
Abstract: PURPOSE: A method and a composition for preventing disruption and aggregation of stem cells are provided to prevent disruption and aggregation of stem cells when the stem cells are stored or delivered and to help stem cells to stably reach a target tissue, thereby effectively enhancing activity of the stem cells. CONSTITUTION: A method for preventing disruption and aggregation of stem cells comprises the step of stem cells in an aspirin-containing solution. Aspirin is selected among isosorbide base aspirin and nicotinic acid base aspirin. The aspirin-containing solution additionally contains a solution selected among a saline solution, a Hartmann-D solution, and phosphate buffered saline (PBS). A stem cell composition for intravascular administration contains stem cells floating in the aspirin-containing solution. [Reference numerals] (AA) Aspirin concentration; (BB) Number of cells
Abstract translation: 目的：提供一种用于预防干细胞破裂和聚集的方法和组合物，用于在干细胞储存或递送时防止干细胞破裂和聚集，并帮助干细胞稳定地达到目标组织，从而有效提高干细胞的活性 干细胞。 构成：用于预防干细胞的破坏和聚集的方法包括在含阿司匹林的溶液中的干细胞的步骤。 阿司匹林选自异山梨醇碱阿司匹林和烟酸碱阿司匹林。 含阿司匹林的溶液另外含有选自盐溶液，Hartmann-D溶液和磷酸盐缓冲盐水（PBS）的溶液。 用于血管内施用的干细胞组合物含有漂浮在含阿司匹林溶液中的干细胞。 [参考数字]（AA）阿司匹林浓度; （BB）细胞数
-
公开(公告)号：KR1020130005247A
公开(公告)日：2013-01-15
申请号：KR1020120073468
申请日：2012-07-05
Applicant: 주식회사 바이오스타코리아 , 라정찬
IPC: G01N33/497 , G01N33/574 , G01N27/62
CPC classification number: G01N33/497 , A61B5/082 , G01N33/57415
Abstract: PURPOSE: A method for measuring breast cancer development or progression using expired gas is provided to analyze expired gas by an electronic nose and to enhance diagnosis sensitivity and specificity. CONSTITUTION: A method for measuring breast cancer development or progression comprises: a step of analyzing collected expired gas by an electronic nose; and a step of detecting gas containing 4-methyl-1,3-benzenediamine, 3-acethyl-2,6-dimethoxypyridine, 2-acethyl-6-methoxypyridine, 2-amino-3-methylbenzoic acid, 2-aminophenylacethic acid, or trichloroethylene. The electronic nose has a mass-spectrometer. [Reference numerals] (AA) Breast cancer; (BB) Breast cancer + thyroid cancer; (CC) Stage 0 breast cancer; (DD) Normal; (EE) Under anticancer therapy
Abstract translation: 目的：提供一种使用过期气体测量乳腺癌发展或进展的方法，以通过电子鼻分析呼出的气体，并增强诊断的敏感性和特异性。 构成：用于测量乳腺癌发展或进展的方法包括：通过电子鼻分析收集的呼出气体的步骤; 检测含有4-甲基-1,3-苯二胺，3-乙酰基-2,6-二甲氧基吡啶，2-乙酰基-6-甲氧基吡啶，2-氨基-3-甲基苯甲酸，2-氨基苯乙酸，或 三氯乙烯。 电子鼻具有质谱仪。 （附图标记）（AA）乳腺癌; （BB）乳腺癌+甲状腺癌; （CC）第0期乳腺癌; （DD）正常; （EE）抗癌治疗
-
公开(公告)号：KR1020120097904A
公开(公告)日：2012-09-05
申请号：KR1020110017442
申请日：2011-02-25
Inventor： 라정찬
IPC: A23L27/40 , B65D85/808
CPC classification number: B65D85/812 , A23L27/40 , B65D75/002
Abstract: PURPOSE: Salt stored in a tea bag capable of easily carrying is provided to enable users to easily adjust the addition amount of the salt when cooking food. CONSTITUTION: Salt stored in a tea bag capable of easily carrying comprises the following: the bag(10) for storing the salt, produced with a material permeable to a salt solution; and a handle string(20) attached to the upper side of the bag. The bag is sealed after storing the salt. The salt is selected from the group consisting of a powder type, a crystalline type, or a granule type.
Abstract translation: 目的：提供储存在能够容易携带的茶包中的盐，以使用户能够在烹饪食物时容易地调节盐的添加量。 构成：储存在能够容易携带的茶袋中的盐包括以下物质：用于储存盐的袋子（10），用可渗透盐溶液的材料制成; 以及附接到袋的上侧的手柄串（20）。 储存盐后密封袋。 该盐选自粉末型，结晶型或颗粒型。
-
公开(公告)号：KR1020040087593A
公开(公告)日：2004-10-14
申请号：KR1020030022038
申请日：2003-04-08
Applicant: 라정찬
CPC classification number: A61K36/07 , A23L33/105 , A23V2002/00 , A23V2200/328 , A61K9/14 , A61K2236/331 , Y10S514/866
Abstract: PURPOSE: Provided is a composition comprising the Inonotus-obliquus extract or its fraction as an active ingredient, for decreasing blood sugar level and preventing and treating diabetes. The Inonotus-obliquus extract has prevention and treatment effect on diabetes and inhibition effect on digestion of polysaccharide to monosaccharide in the small intestine. CONSTITUTION: The composition for decreasing blood sugar level and preventing and treating diabetes is characterized by containing the Inonotus-obliquus extract or its fraction, as well as pharmaceutically acceptable carrier. The composition further contains Morus alba L., Morus alba Linne, Lycium chinensis, Pueraria thunbergiana(SIEB.et ZUCC) BENTH, Liliope platyphylla Wang et Tang, Asparagus cochinchinensis, or the mixture thereof.
Abstract translation: 目的：提供含有Inonotus-obliquus提取物或其级分作为活性成分的组合物，用于降低血糖水平和预防和治疗糖尿病。 Inonotus-obliquus提取物对糖尿病具有预防和治疗作用，对小肠中多糖对单糖的消化具有抑制作用。 构成：用于降低血糖水平和预防和治疗糖尿病的组合物的特征在于含有Inonotus-obliquus提取物或其部分，以及药学上可接受的载体。 该组合物还含有桑contains，桑ba，枸杞，葛根（Pueraria thunbergiana）（SIEB.et ZUCC）BENTH，Liliope platyphylla Wang et Tang，芦笋香茅或其混合物。
-
-
-
-
-
-
-
Search Results
48
records
(took 0.022 seconds)
